Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
112 hedge funds and large institutions have $1.51B invested in Mirati Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 48 increasing their positions, 31 reducing their positions, and 32 closing their positions.
107% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $2.85M
55% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 31
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5% less capital invested
Capital invested by funds: $1.58B → $1.51B (-$75.9M)
10% less funds holding
Funds holding: 125 → 112 (-13)
38% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$25.8M |
| 2 |
BlackRock
New York
|
+$18.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16.9M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$15.2M |
| 5 |
O
OppenheimerFunds
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$15.3M |
| 2 |
PC
PointState Capital
New York
|
-$11.4M |
| 3 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$9.45M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$9.02M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.42M |
MRTX Hedge Fund Activity: Q4 2018 in Review
112 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2018, worth a combined $1.51B — down 4.8% from $1.58B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of MRTX and 20 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 48 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $25.8M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $15.3M sold.
- 112 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2018, down from 125 in Q3 2018.
- Funds reported $1.51B of Mirati Therapeutics, Inc. Common Stock stock for Q4 2018, down 4.8% quarter-over-quarter.
- 20 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2018 and 32 closed out, a net change of -12 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2018 was EcoR1 Capital, an estimated $25.8M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2018 was Marshall Wace North America, an estimated $15.3M sold.
Based on aggregated 13F filings for Q4 2018.